Purpose: Tendinopathy shows early disorganized collagen fibers with neo-angiogenesis on histology.Peri-tendinous injection of corticosteroid is the commonly accepted strategy despite the abscence ofinflammation in tendinosis. The aim of our study was to assess the potential of intratendinous injectionof an anti-angiogenic drug (bevacizumab, AA) to treat tendinopathy in a murine model of patellar andAchilles tendinopathy, and to evaluate its local toxicity.Materials and method: Forty rats (160 patellar and Achilles tendons) were used for this study. We inducedtendinosis (T+) in 80 tendons by injecting under ultrasonography (US) guidance Collagenase 1(day0 = D0, patellar = 40 and Achilles = 40). Clinical examination and tendon US were performed at D3, imme-diately followed by either AA (AAT+, n = 40) or physiological serum (PST+, n = 40, control) US-guidedintratendinous injection. Follow-up at D6 and D13 using clinical, US and histology, and comparisonbetween the 2 groups were performed. To study AA toxicity we compared the 80 remaining normaltendons (T?) after injecting AA in 40 (AAT?).Results: All AAT+ showed a better joint mobilization compared to PST+ at D6 (p = 0.004) with thinner UStendon diameters (p <0.004), and less disorganized collagen fibers and neovessels on histology (p <0.05).There was no difference at D13 regarding clinical status, US tendon diameter and histology (p > 0.05).Comparison between AAT? and T? showed no AA toxicity on tendon (p = 0.18).Conclusion: Our study suggests that high dose mono-injection of AA in tendinosis, early after the beginningof the disease, accelerates tendon's healing, with no local toxicity.
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging